The administration of methotrexate in patients with Still’s disease, “real-life” findings from AIDA Network Still Disease Registry

362. Ruscitti P; J Sota; A Vitale; G Lopalco; F Iannone; M Morrone; Ham Giardini; Ma D'Agostin; Ipb Antonelli; I Almaghlouth; Kn Asfina; N Khalil; Pp Sfikakis; K Laskari; M Tektonidou; F Ciccia; D Iacono; F Riccio; G Ragab; Ma Hussein; M Govoni; F Ruffilli; H Direskeneli; F Alibaz-Oner; R Giacomelli; L Navarini; E Bartoloni; I Riccucci; E Martín-Nares; J Torres-Ruiz; P Cipriani; I Di Cola; J Hernández-Rodríguez; V Gómez-Caverzaschi; L Dagna; A Tomelleri; J Makowska; O Brzezinska; A Iagnocco; E Bellis; V Caggiano; C Gaggiano; M Tarsia; I Mormile; G Emmi; P Sfriso; S Monti; Ş Erten; E Del Giudice; R Lubrano; G Conti; An Olivieri; A Lo Gullo; S Tharwat; A Karamanakos; A Gidaro; Mc Maggio; F La Torre; F Cardinale; B Ogunjimi; A Maier; Gd Sebastiani; D Opris-Belinski; M Frassi; O Viapiana; E Bizzi; F Carubbi; L Fotis; A Tufan; Rc Kardas; E Więsik-Szewczyk; K Jahnz-Różyk; C Fabiani; B Frediani; A Balistreri; Donato Rigante; L Cantarini

doi:10.1016/j.semarthrit.2023.152244

The administration of methotrexate in patients with Still’s disease, “real-life” findings from AIDA Network Still Disease Registry

362. Ruscitti P, J Sota, A Vitale, G Lopalco, F Iannone, M Morrone, Ham Giardini, Ma D'Agostin, Ipb Antonelli, I Almaghlouth, Kn Asfina, N Khalil, Pp Sfikakis, K Laskari, M Tektonidou, F Ciccia, D Iacono, F Riccio, G Ragab, Ma HusseinM Govoni, F Ruffilli, H Direskeneli, F Alibaz-Oner, R Giacomelli, L Navarini, E Bartoloni, I Riccucci, E Martín-Nares, J Torres-Ruiz, P Cipriani, I Di Cola, J Hernández-Rodríguez, V Gómez-Caverzaschi, L Dagna, A Tomelleri, J Makowska, O Brzezinska, A Iagnocco, E Bellis, V Caggiano, C Gaggiano, M Tarsia, I Mormile, G Emmi, P Sfriso, S Monti, Ş Erten, E Del Giudice, R Lubrano, G Conti, An Olivieri, A Lo Gullo, S Tharwat, A Karamanakos, A Gidaro, Mc Maggio, F La Torre, F Cardinale, B Ogunjimi, A Maier, Gd Sebastiani, D Opris-Belinski, M Frassi, O Viapiana, E Bizzi, F Carubbi, L Fotis, A Tufan, Rc Kardas, E Więsik-Szewczyk, K Jahnz-Różyk, C Fabiani, B Frediani, A Balistreri, Donato Rigante, L Cantarini

Research output: Contribution to journal › Article

Abstract

Objectives: To describe clinical characteristics of patients with Still's disease treated with methotrexate (MTX) and to assess drug effectiveness evaluating change in disease activity, reduction of inflammatory markers, and glucocorticoid (GC)-sparing effect. Methods: Patients with Still's disease treated with MTX were assessed among those included in AIDA Network Still Disease Registry. Results: In this registry, 171 patients with Still's disease were treated with MTX (males 43.3%, age 37.1 ± 16.0 years). They were mainly characterised by joint features and fever without a prominent multiorgan involvement. MTX was administered with GCs in 68.4% of patients, with other conventional synthetic DMARDs in 6.4%, and with biologic DMARDs in 25.1%. A significant reduction of the modified systemic score was observed, and 38.6% patients were codified as being in clinical remission at the end of follow-up. The concomitant administration of a biologic DMARD resulted a predictor of the clinical remission. Furthermore, a reduction of inflammatory markers and ferritin levels was observed following the administration of MTX. Additionally, a marked reduction of the dosage of concomitant GCs was identified, while 36.7% discontinued such drugs. Male gender appeared as a predictor of GC discontinuation. MTX was discontinued in 12.3% of patients because of adverse effects, and in 12.3% for lack of efficacy. Conclusions: Clinical characteristics of patients with Still's disease treated with MTX were described, mainly joint features and fever without a prominent multiorgan involvement. The clinical usefulness of MTX was reported in reducing the disease activity, decreasing the inflammatory markers, and as GC-sparing agent.

Original language	English
Pages (from-to)	1-26
Number of pages	26
Journal	Seminars in Arthritis and Rheumatism
Volume	2023
DOIs	https://doi.org/10.1016/j.semarthrit.2023.152244
Publication status	Published - 2023

Keywords

Still's disease

Access to Document

10.1016/j.semarthrit.2023.152244

Cite this

Ruscitti P, ., Sota, J., Vitale, A., Lopalco, G., Iannone, F., Morrone, M., Giardini, H., D'Agostin, M., Antonelli, I., Almaghlouth, I., Asfina, K., Khalil, N., Sfikakis, P., Laskari, K., Tektonidou, M., Ciccia, F., Iacono, D., Riccio, F., Ragab, G., ... Cantarini, L. (2023). The administration of methotrexate in patients with Still’s disease, “real-life” findings from AIDA Network Still Disease Registry. Seminars in Arthritis and Rheumatism, 2023, 1-26. https://doi.org/10.1016/j.semarthrit.2023.152244

@article{11aba0d4b58749a1a05632119fd10cd4,

title = "The administration of methotrexate in patients with Still{\textquoteright}s disease, “real-life” findings from AIDA Network Still Disease Registry",

abstract = "Objectives: To describe clinical characteristics of patients with Still's disease treated with methotrexate (MTX) and to assess drug effectiveness evaluating change in disease activity, reduction of inflammatory markers, and glucocorticoid (GC)-sparing effect. Methods: Patients with Still's disease treated with MTX were assessed among those included in AIDA Network Still Disease Registry. Results: In this registry, 171 patients with Still's disease were treated with MTX (males 43.3%, age 37.1 ± 16.0 years). They were mainly characterised by joint features and fever without a prominent multiorgan involvement. MTX was administered with GCs in 68.4% of patients, with other conventional synthetic DMARDs in 6.4%, and with biologic DMARDs in 25.1%. A significant reduction of the modified systemic score was observed, and 38.6% patients were codified as being in clinical remission at the end of follow-up. The concomitant administration of a biologic DMARD resulted a predictor of the clinical remission. Furthermore, a reduction of inflammatory markers and ferritin levels was observed following the administration of MTX. Additionally, a marked reduction of the dosage of concomitant GCs was identified, while 36.7% discontinued such drugs. Male gender appeared as a predictor of GC discontinuation. MTX was discontinued in 12.3% of patients because of adverse effects, and in 12.3% for lack of efficacy. Conclusions: Clinical characteristics of patients with Still's disease treated with MTX were described, mainly joint features and fever without a prominent multiorgan involvement. The clinical usefulness of MTX was reported in reducing the disease activity, decreasing the inflammatory markers, and as GC-sparing agent.",

keywords = "Still's disease, Still's disease",

author = "{Ruscitti P}, 362. and J Sota and A Vitale and G Lopalco and F Iannone and M Morrone and Ham Giardini and Ma D'Agostin and Ipb Antonelli and I Almaghlouth and Kn Asfina and N Khalil and Pp Sfikakis and K Laskari and M Tektonidou and F Ciccia and D Iacono and F Riccio and G Ragab and Ma Hussein and M Govoni and F Ruffilli and H Direskeneli and F Alibaz-Oner and R Giacomelli and L Navarini and E Bartoloni and I Riccucci and E Mart{\'i}n-Nares and J Torres-Ruiz and P Cipriani and {Di Cola}, I and J Hern{\'a}ndez-Rodr{\'i}guez and V G{\'o}mez-Caverzaschi and L Dagna and A Tomelleri and J Makowska and O Brzezinska and A Iagnocco and E Bellis and V Caggiano and C Gaggiano and M Tarsia and I Mormile and G Emmi and P Sfriso and S Monti and {\c S} Erten and {Del Giudice}, E and R Lubrano and G Conti and An Olivieri and {Lo Gullo}, A and S Tharwat and A Karamanakos and A Gidaro and Mc Maggio and {La Torre}, F and F Cardinale and B Ogunjimi and A Maier and Gd Sebastiani and D Opris-Belinski and M Frassi and O Viapiana and E Bizzi and F Carubbi and L Fotis and A Tufan and Rc Kardas and E Wi{\c e}sik-Szewczyk and K Jahnz-R{\'o}{\.z}yk and C Fabiani and B Frediani and A Balistreri and Donato Rigante and L Cantarini",

year = "2023",

doi = "10.1016/j.semarthrit.2023.152244",

language = "English",

volume = "2023",

pages = "1--26",

journal = "Seminars in Arthritis and Rheumatism",

issn = "0049-0172",

publisher = "W B Saunders Company:Fulfillment Department, The Curtis Center, Independence Square West:Philadelphia, PA 19106:(800)654-2452, (215)238-7800, EMAIL: [email protected], INTERNET: http://elsevierhealth.com, Fax: (215)238-6445",

}

Ruscitti P, Sota, J, Vitale, A, Lopalco, G, Iannone, F, Morrone, M, Giardini, H, D'Agostin, M, Antonelli, I, Almaghlouth, I, Asfina, K, Khalil, N, Sfikakis, P, Laskari, K, Tektonidou, M, Ciccia, F, Iacono, D, Riccio, F, Ragab, G, Hussein, M, Govoni, M, Ruffilli, F, Direskeneli, H, Alibaz-Oner, F, Giacomelli, R, Navarini, L, Bartoloni, E, Riccucci, I, Martín-Nares, E, Torres-Ruiz, J, Cipriani, P, Di Cola, I, Hernández-Rodríguez, J, Gómez-Caverzaschi, V, Dagna, L, Tomelleri, A, Makowska, J, Brzezinska, O, Iagnocco, A, Bellis, E, Caggiano, V, Gaggiano, C, Tarsia, M, Mormile, I, Emmi, G, Sfriso, P, Monti, S, Erten, Ş, Del Giudice, E, Lubrano, R, Conti, G, Olivieri, A, Lo Gullo, A, Tharwat, S, Karamanakos, A, Gidaro, A, Maggio, M, La Torre, F, Cardinale, F, Ogunjimi, B, Maier, A, Sebastiani, G, Opris-Belinski, D, Frassi, M, Viapiana, O, Bizzi, E, Carubbi, F, Fotis, L, Tufan, A, Kardas, R, Więsik-Szewczyk, E, Jahnz-Różyk, K, Fabiani, C, Frediani, B, Balistreri, A, Rigante, D & Cantarini, L 2023, 'The administration of methotrexate in patients with Still’s disease, “real-life” findings from AIDA Network Still Disease Registry', Seminars in Arthritis and Rheumatism, vol. 2023, pp. 1-26. https://doi.org/10.1016/j.semarthrit.2023.152244

TY - JOUR

T1 - The administration of methotrexate in patients with Still’s disease, “real-life” findings from AIDA Network Still Disease Registry

AU - Ruscitti P, 362.

AU - Sota, J

AU - Vitale, A

AU - Lopalco, G

AU - Iannone, F

AU - Morrone, M

AU - Giardini, Ham

AU - D'Agostin, Ma

AU - Antonelli, Ipb

AU - Almaghlouth, I

AU - Asfina, Kn

AU - Khalil, N

AU - Sfikakis, Pp

AU - Laskari, K

AU - Tektonidou, M

AU - Ciccia, F

AU - Iacono, D

AU - Riccio, F

AU - Ragab, G

AU - Hussein, Ma

AU - Govoni, M

AU - Ruffilli, F

AU - Direskeneli, H

AU - Alibaz-Oner, F

AU - Giacomelli, R

AU - Navarini, L

AU - Bartoloni, E

AU - Riccucci, I

AU - Martín-Nares, E

AU - Torres-Ruiz, J

AU - Cipriani, P

AU - Di Cola, I

AU - Hernández-Rodríguez, J

AU - Gómez-Caverzaschi, V

AU - Dagna, L

AU - Tomelleri, A

AU - Makowska, J

AU - Brzezinska, O

AU - Iagnocco, A

AU - Bellis, E

AU - Caggiano, V

AU - Gaggiano, C

AU - Tarsia, M

AU - Mormile, I

AU - Emmi, G

AU - Sfriso, P

AU - Monti, S

AU - Erten, Ş

AU - Del Giudice, E

AU - Lubrano, R

AU - Conti, G

AU - Olivieri, An

AU - Lo Gullo, A

AU - Tharwat, S

AU - Karamanakos, A

AU - Gidaro, A

AU - Maggio, Mc

AU - La Torre, F

AU - Cardinale, F

AU - Ogunjimi, B

AU - Maier, A

AU - Sebastiani, Gd

AU - Opris-Belinski, D

AU - Frassi, M

AU - Viapiana, O

AU - Bizzi, E

AU - Carubbi, F

AU - Fotis, L

AU - Tufan, A

AU - Kardas, Rc

AU - Więsik-Szewczyk, E

AU - Jahnz-Różyk, K

AU - Fabiani, C

AU - Frediani, B

AU - Balistreri, A

AU - Rigante, Donato

AU - Cantarini, L

PY - 2023

Y1 - 2023

N2 - Objectives: To describe clinical characteristics of patients with Still's disease treated with methotrexate (MTX) and to assess drug effectiveness evaluating change in disease activity, reduction of inflammatory markers, and glucocorticoid (GC)-sparing effect. Methods: Patients with Still's disease treated with MTX were assessed among those included in AIDA Network Still Disease Registry. Results: In this registry, 171 patients with Still's disease were treated with MTX (males 43.3%, age 37.1 ± 16.0 years). They were mainly characterised by joint features and fever without a prominent multiorgan involvement. MTX was administered with GCs in 68.4% of patients, with other conventional synthetic DMARDs in 6.4%, and with biologic DMARDs in 25.1%. A significant reduction of the modified systemic score was observed, and 38.6% patients were codified as being in clinical remission at the end of follow-up. The concomitant administration of a biologic DMARD resulted a predictor of the clinical remission. Furthermore, a reduction of inflammatory markers and ferritin levels was observed following the administration of MTX. Additionally, a marked reduction of the dosage of concomitant GCs was identified, while 36.7% discontinued such drugs. Male gender appeared as a predictor of GC discontinuation. MTX was discontinued in 12.3% of patients because of adverse effects, and in 12.3% for lack of efficacy. Conclusions: Clinical characteristics of patients with Still's disease treated with MTX were described, mainly joint features and fever without a prominent multiorgan involvement. The clinical usefulness of MTX was reported in reducing the disease activity, decreasing the inflammatory markers, and as GC-sparing agent.

AB - Objectives: To describe clinical characteristics of patients with Still's disease treated with methotrexate (MTX) and to assess drug effectiveness evaluating change in disease activity, reduction of inflammatory markers, and glucocorticoid (GC)-sparing effect. Methods: Patients with Still's disease treated with MTX were assessed among those included in AIDA Network Still Disease Registry. Results: In this registry, 171 patients with Still's disease were treated with MTX (males 43.3%, age 37.1 ± 16.0 years). They were mainly characterised by joint features and fever without a prominent multiorgan involvement. MTX was administered with GCs in 68.4% of patients, with other conventional synthetic DMARDs in 6.4%, and with biologic DMARDs in 25.1%. A significant reduction of the modified systemic score was observed, and 38.6% patients were codified as being in clinical remission at the end of follow-up. The concomitant administration of a biologic DMARD resulted a predictor of the clinical remission. Furthermore, a reduction of inflammatory markers and ferritin levels was observed following the administration of MTX. Additionally, a marked reduction of the dosage of concomitant GCs was identified, while 36.7% discontinued such drugs. Male gender appeared as a predictor of GC discontinuation. MTX was discontinued in 12.3% of patients because of adverse effects, and in 12.3% for lack of efficacy. Conclusions: Clinical characteristics of patients with Still's disease treated with MTX were described, mainly joint features and fever without a prominent multiorgan involvement. The clinical usefulness of MTX was reported in reducing the disease activity, decreasing the inflammatory markers, and as GC-sparing agent.

KW - Still's disease

UR - http://hdl.handle.net/10807/245235

U2 - 10.1016/j.semarthrit.2023.152244

DO - 10.1016/j.semarthrit.2023.152244

M3 - Article

SN - 0049-0172

VL - 2023

SP - 1

EP - 26

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

ER -

The administration of methotrexate in patients with Still’s disease, “real-life” findings from AIDA Network Still Disease Registry

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this